Ivonescimab Cuts Death Risk 27% vs Keytruda in HARMONi-2 — Full OS Data Land Ahead of WCLC
SMMT sits 50% above its 52-week low of $12.07.
Summary
Full HARMONi-2 overall survival data show ivonescimab beat pembrolizumab with a 27% reduction in death risk and 8.2-month median OS improvement, with the strongest benefit in PD-L1 high patients (HR 0.58).
Key Events · Product Development and Regulatory · SMMT
-
HARMONi-2 OS Data Beat Pembrolizumab
Ivonescimab monotherapy achieved median OS of 30.8 months vs 22.6 months for pembrolizumab (HR 0.73, 95% CI: 0.57-0.95, p=0.009) in PD-L1-positive advanced NSCLC, a 27% reduction in death risk.
-
PD-L1 High Subgroup Shows Strongest Benefit
In patients with PD-L1 score ≥50% (n=168), ivonescimab delivered HR 0.58 (95% CI: 0.38-0.89), supporting the design of the ongoing global HARMONi-7 registrational study.
-
Safety Profile Remains Manageable
Serious treatment-related adverse events were 29.9% for ivonescimab vs 21.6% for pembrolizumab; discontinuation rates were 4.1% vs 5.0%, with no new safety signals at 36-month follow-up.
-
Fourth Positive Phase III OS Readout
HARMONi-2 becomes the fourth Phase III study of ivonescimab to show statistically significant OS and PFS improvements against standard-of-care regimens, following HARMONi, HARMONi-A, and HARMONi-6.
Analysis · SMMT · Life Sciences
Summit's partner Akeso released the complete overall survival dataset from the Phase III HARMONi-2 trial, showing ivonescimab monotherapy reduced the risk of death by 27% versus pembrolizumab (HR 0.73, p=0.009) with a median OS advantage of 8.2 months. The PD-L1 high subgroup showed an even stronger HR of 0.58. This is the fourth Phase III study to show a statistically significant OS benefit for ivonescimab against standard of care, reinforcing the drug's potential to displace pembrolizumab in first-line NSCLC. The data lands two months before the November 14, 2026 PDUFA date for the HARMONi BLA, and directly de-risks the ongoing global HARMONi-7 registrational study. Against the backdrop of the company's going-concern warning from Q2 2026, positive data of this magnitude strengthens both the regulatory case and the company's ability to raise additional capital.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.8% of the 990 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SMMT was trading at $18.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14B. The 52-week trading range was $12.07 to $29.23. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.